Published on 08/12/2025

Bridging Assays Across Sites: Equivalence and Bias

In the rapidly evolving realm of pharmaceuticals, particularly within the context of biologics and advanced therapy medicinal products (ATMPs), ensuring consistency and reliability in assay performance across different sites is paramount. This article discusses bridging assays across different clinical sites by emphasizing the importance of equivalence and bias evaluation, specifically in the context of critical parameters such as viral clearance validation, spiking studies, and the use of closed and single-use systems. The goal of this guide is to provide a comprehensive framework for professionals engaged in the planning, execution, and regulatory compliance of these validation processes.

Understanding the Importance of Bridging Studies

Bridging studies serve as a fundamental mechanism to establish consistency in results when assays are performed across multiple sites. This is particularly crucial for biologics and ATMP products that often undergo complex manufacturing processes and are subject to stringent regulatory scrutiny. Bridging studies typically focus on evaluating the assay’s equivalence, ensuring that any deviations in assay results are well-characterized and understood.

From a regulatory standpoint, the FDA guidance on process validation emphasizes the need for rigorous documentation and characterization in process validation, including the assessment of critical quality attributes (CQAs). In line with the FDA’s recommendations, bridging studies must evaluate the points of variability and ensure that any bias in the assay results does not compromise product quality or patient safety.

Furthermore, bridging studies must be carefully planned and executed to comply with the expectations set forth by regulatory bodies like the EMA, offering a framework that fosters international standardization and acceptance of assay results across different markets.

Planning Bridge Studies: Key Considerations

When planning bridging studies, particularly for viral clearance validation and spiking studies, several key considerations must be integrated into the overall strategy. This includes defining objectives, establishing timelines, and selecting appropriate sites. The following steps outline a detailed plan for setting up these studies:

• Define Objectives: Begin by clearly defining the objectives of the bridging study. Identify what equivalence means in the context of your assays, whether in terms of accuracy, precision, or specificity. Additionally, document the acceptable limits for bias.
• Select Sites: Choose the clinical or analytical sites based on their capabilities, infrastructure, and expertise in conducting the assays. This step should also include evaluating the staff’s qualifications and training to ensure consistency in performing assays.
• Develop a Study Protocol: Prepare a detailed protocol that outlines study design, methodology, assay validation parameters, and statistical analysis plan. The protocol should be compliant with relevant guidelines such as ICH Q5A(R2) and include considerations for potential geographical and logistical variabilities.
• Establish Assay Controls: Ensure proper implementation of aseptic controls and quality checks to maintain the integrity of the studies, particularly in closed systems and single-use systems. Consult the Annex 1 of the EU GMP Guidelines for directives related to sterile product manufacture and quality controls.
• Document Chain of Identity Custody: Implement rigorous documentation to ensure a clear chain of identity custody (COI) and chain of custody (COC), safeguarding the traceability of samples and data integrity.

By methodically addressing these key considerations, a robust framework for bridging studies can be developed which aligns with regulatory expectations and institutional best practices.

Executing Bridging Studies: Methodology and Best Practices

The execution of bridging studies involves a series of methodical steps that ensure compliance with both internal and regulatory requirements. The following procedure outlines the best practices for conducting successful bridging studies:

• Training Personnel: Conduct comprehensive training sessions for all personnel involved in the study. Emphasize the importance of adhering to standard operating procedures (SOPs), and ensure everyone is well-versed in the protocol and quality assurance expectations.
• Sample Preparation: Follow uniform sample preparation protocols across all sites. This includes proper handling and storage of samples to prevent degradation and variability. Consistent spiking studies should be performed using the same biological matrix and spiking agents to minimize variability.
• Data Collection and Management: Implement a reliable data collection strategy using validated electronic systems to ensure real-time access to study data. This not only promotes transparency but also facilitates efficient statistical analysis.
• Process Monitoring: Continuously monitor the assay performance through process parameters established during the planning phase. Regularly review and analyze data to identify any trends or deviations. This is critical for maintaining a high standard of quality throughout the life of the study.
• Conduct Statistical Analysis: Once data is collected, perform rigorous statistical analyses to assess the equivalence of assay results across sites. Utilize appropriate statistical methods to evaluate potential bias and ensure that results fall within the predefined acceptable limits.

These practices form the foundation of executing bridging studies effectively, ultimately contributing to the demonstration of assay comparability and reliability across different sites.

Regulatory Compliance and Documentation

The importance of thorough documentation cannot be overstated when it comes to bridging studies. Regulatory authorities such as the FDA and EMA emphasize the need for comprehensive documentation throughout the validation process. Here are key elements to consider regarding documentation:

• Study Protocols: Document everything from study design to execution in detail, including sample handling and data collection processes. This should also include any modifications made to protocols during the study and explanations for those changes.
• Data Integrity: Ensure data integrity by maintaining thorough records of all assay results, deviations, and corrective actions taken. This documentation should be safeguarded against tampering and be easily retrievable for audits.
• Final Study Reports: Upon completion of the study, compile a final report that summarizes objectives, methodology, results, statistical evaluations, and conclusions. Ensure this is written in a clear and concise manner, adhering to regulatory standards.
• Regulatory Submissions: Prepare for regulatory submissions by aligning the bridging study documentation with the requirements set by both the FDA and EMA. This ensures that all data presented is consistent, reproducible, and categorized according to submission guidelines such as the Common Technical Document (CTD).

The role of detailed documentation is crucial, as it supports compliance efforts while also laying a foundation for transparent communication with regulatory authorities.

Conclusion: Ensuring Quality through Bridging Studies

Bridging assays across sites is an intricate yet essential process within the realm of biologics and ATMPs, playing a significant role in viral clearance validation and the assessment of critical control points in assay performance. By understanding the underlying principles, carefully planning, executing with precision, and adhering to regulatory guidelines, pharmaceutical professionals can ensure that bridging studies produce reliable, consistent, and compliant data.

Overall, the aim should always be to uphold product quality and patient safety through meticulous validation practices. With a structured approach to bridging studies, utilizing closed systems, single-use systems, and rigorous spiking studies, pharmaceutical professionals can successfully navigate the complexities of assay equivalence and bias among diverse clinical and analytical environments.